Trial reportInternational journal of cancer2011
Dietary vitamin D intake and serum 25-hydroxyvitamin D level in relation to disease outcomes in head and neck cancer patients.
Trial report in International journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00169845 (Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients), which is not on this map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Beta-carotene and Alpha-tocopherol Chemoprevention of Second Primary Malignancies in Head and Neck Cancer Patients
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Association Between Vitamin D Exposure and Head and Neck Cancer: A Systematic Review With Meta-Analysis.Frontiers in immunology · 2021Pooled it
- Vitamin D in Head and Neck Cancer: a Systematic Review.Current oncology reports · 2020Pooled it
- The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis.British journal of cancer · 2017Pooled it
- Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies.BMJ (Clinical research ed.) · 2014Pooled it
- Serum 25-hydroxyvitamin D and risk of oropharynx and larynx cancers in Finnish men.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2011Trial
- Genetically predicted vitamin D levels and risk of head and neck cancer: a mendelian randomization study.Cancer causes & control : CCC · 2026Article
- Impact of vitamin D deficiency on disease outcomes in patients with oral squamous cell carcinoma: a retrospective cohort study.Irish journal of medical science · 2026Article
- Season of radiotherapy and outcomes of head & neck cancer patients in the MACH-NC & MARCH meta-analyses.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- The association between the Mediterranean Diet Score and death from cancer of the head and neck.Cancer causes & control : CCC · 2024Article
- Role of Vitamin D in Head and Neck Cancer-Immune Function, Anti-Tumour Effect, and Its Impact on Patient Prognosis.Nutrients · 2023Review
- Vitamin D intake and survival and recurrence in head and neck cancer patients.The Laryngoscope · 2018Article
- In serum, higher parathyroid hormone but not lower vitamin D is associated with oral squamous cell carcinoma.Current oncology (Toronto, Ont.) · 2015Article
- The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: Discussion of Causation.Cancers · 2013Article
- Postdiagnosis supplement use and breast cancer prognosis in the After Breast Cancer Pooling Project.Breast cancer research and treatment · 2013Article
- Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis.The American journal of clinical nutrition · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Low pretreatment vitamin D status has been associated with worsened disease outcomes in patients with cancer at various sites. Its prognostic significance in head and neck cancer (HNC) patients has not been studied. Patients with HNC who participated in a randomized trial were evaluated for: (i) total intake of vitamin D from diet and supplements using a validated food frequency questionnaire (all trial participants, n = 540) and (ii) pretreatment serum 25-hydroxyvitamin D through a radioimmunoassay (n = 522). The association of dietary/serum measures of vitamin D status with HNC recurrence, second primary cancer (SPC) incidence, and overall mortality was evaluated using multivariate Cox proportional hazard models. There was no significant association between dietary or serum vitamin D measures and the three HNC outcomes. The hazard ratios (HRs) comparing the highest with the lowest quartile of dietary/supplemental vitamin D intake were 1.10 (95% confidence interval (CI): 0.66-1.84) for recurrence, 1.05 (95% CI: 0.63-1.74) for SPC, and 1.27 (95% CI: 0.87-1.84) for overall mortality. HRs comparing the uppermost to the lowest quartile of serum 25-hydroxyvitamin D levels were 1.12 (95% CI: 0.65-1.93) for recurrence, 0.72 (95% CI: 0.40-1.30) for SPC, and 0.85 (95% CI: 0.57-1.28) for overall mortality. There was no effect modification by cancer stage, season of initial treatment, or trial arm. Among patients with HNC, vitamin D status before treatment does not influence disease outcomes. Our results contrast with those from most published studies, which suggest prognostic significance of vitamin D status in cancer patients at least in subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.